301015 百洋医药
已收盘 08-19 15:00:00
资讯
新帖
简况
百洋医药（301015）披露归还临时补充流动资金的闲置募集资金公告，8月10日股价上涨1.51%
证券之星 · 08-10
百洋医药（301015）披露归还临时补充流动资金的闲置募集资金公告，8月10日股价上涨1.51%
百洋医药新提交“迪巧小粉条”商标注册申请
证券之星 · 08-08
百洋医药新提交“迪巧小粉条”商标注册申请
7月17日百洋医药跌6.32%，益民创新优势混合A基金重仓该股
证券之星 · 07-17
7月17日百洋医药跌6.32%，益民创新优势混合A基金重仓该股
百洋医药：提供ZAP-X放疗设备及配套技术支持
证券之星 · 07-17
百洋医药：提供ZAP-X放疗设备及配套技术支持
百洋医药（301015）披露为子公司提供担保的进展公告，7月9日股价上涨2.94%
证券之星 · 07-09
百洋医药（301015）披露为子公司提供担保的进展公告，7月9日股价上涨2.94%
百洋医药：不存在使用募集资金解除控股股东股票质押的情形
证券之星 · 07-08
百洋医药：不存在使用募集资金解除控股股东股票质押的情形
7月1日百洋医药涨5.46%，益民创新优势混合A基金重仓该股
证券之星 · 07-01
7月1日百洋医药涨5.46%，益民创新优势混合A基金重仓该股
百洋医药：控股股东所持股份质押比例处于合理可控范围
证券之星 · 07-01
百洋医药：控股股东所持股份质押比例处于合理可控范围
股市必读：百洋医药（301015）6月29日董秘有最新回复
证券之星 · 06-30
股市必读：百洋医药（301015）6月29日董秘有最新回复
百洋医药（301015）披露拟发行H股并在港交所主板上市议案，6月29日股价上涨3.45%
证券之星 · 06-29
百洋医药（301015）披露拟发行H股并在港交所主板上市议案，6月29日股价上涨3.45%
百洋医药：公司目前经营一切正常
证券之星 · 06-29
百洋医药：公司目前经营一切正常
百洋医药：公司及控股子公司无逾期担保情况
证券日报 · 06-26
百洋医药：公司及控股子公司无逾期担保情况
股市必读：百洋医药（301015）6月23日董秘有最新回复
证券之星 · 06-24
股市必读：百洋医药（301015）6月23日董秘有最新回复
百洋医药：锝[99mTc]佩昔瑞特加肽注射液是我国第一个自主研发的核医学1类创新药
证券之星 · 06-23
百洋医药：锝[99mTc]佩昔瑞特加肽注射液是我国第一个自主研发的核医学1类创新药
6月22日百洋医药跌6.91%，益民创新优势混合A基金重仓该股
证券之星 · 06-22
6月22日百洋医药跌6.91%，益民创新优势混合A基金重仓该股
每周股票复盘：百洋医药（301015）百洋转债或触向下修正条件
证券之星 · 06-21
每周股票复盘：百洋医药（301015）百洋转债或触向下修正条件
百洋医药：为深入推进公司全球化发展战略及海外业务布局
证券之星 · 06-18
百洋医药：为深入推进公司全球化发展战略及海外业务布局
百洋医药（301015）披露关于预计触发百洋转债转股价格向下修正条件的提示性公告，6月16日股价下跌0.39%
证券之星 · 06-16
百洋医药（301015）披露关于预计触发百洋转债转股价格向下修正条件的提示性公告，6月16日股价下跌0.39%
百洋医药最新公告：筹划发行H股并在香港联交所主板上市
证券之星 · 06-10
百洋医药最新公告：筹划发行H股并在香港联交所主板上市
百洋医药：纽特舒玛国内蝉联进口纯乳清蛋白粉销售额第一
证券之星 · 06-04
百洋医药：纽特舒玛国内蝉联进口纯乳清蛋白粉销售额第一
加载更多
公司概况
公司名称：
青岛百洋医药股份有限公司
所属行业：
批发业
上市日期：
2021-06-30
主营业务：
青岛百洋医药股份有限公司核心业务聚焦医学创新成果的产品开发、生产制造和商业化运营,公司深度布局创新药与创新医疗器械，聚焦骨健康、抗器官纤维化、肿瘤脑转移、心血管等前沿领域，通过投资、研发转化与产业化平台运营，构建从源头创新到临床落地的全链条产业生态。公司的主要产品是药品、医疗器械、品牌服务。
发行价格：
7.64
{"stockData":{"symbol":"301015","market":"SZ","secType":"STK","nameCN":"百洋医药","latestPrice":26,"timestamp":1787123016000,"preClose":26.78,"halted":0,"volume":15916555,"delay":0,"changeRate":-0.0291,"floatShares":526000000,"shares":526000000,"eps":0.9772,"marketStatus":"已收盘","change":-0.78,"latestTime":"08-19 15:00:00","open":26.6,"high":27.48,"low":25.9,"amount":423000000,"amplitude":0.059,"askPrice":26.01,"askSize":1,"bidPrice":26,"bidSize":103,"shortable":0,"etf":0,"ttmEps":0.9772,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787189400000},"marketStatusCode":5,"adr":0,"adjPreClose":26.78,"symbolType":"stock","openAndCloseTimeList":[[1787103000000,1787110200000],[1787115600000,1787122800000]],"highLimit":29.46,"lowLimit":24.1,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":525624077,"isCdr":false,"pbRate":5.66,"roa":"--","peRate":26.606631,"roe":"5.11%","epsLYR":0.9,"committee":0.950549,"marketValue":13666000000,"turnoverRate":0.0303,"status":1,"floatMarketCap":13664000000},"requestUrl":"/m/hq/s/301015/","defaultTab":"news","newsList":[{"id":"2658442932","title":"百洋医药（301015）披露归还临时补充流动资金的闲置募集资金公告，8月10日股价上涨1.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658442932","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658442932?lang=zh_cn&edition=full","pubTime":"2026-08-10 22:28","pubTimestamp":1786372105,"startTime":"0","endTime":"0","summary":"截至2026年8月10日收盘，百洋医药报收于24.23元，较前一交易日上涨1.51%，最新总市值为127.36亿元。该股当日开盘24.14元，最高24.57元，最低23.8元，成交额达2.39亿元，换手率为1.88%。公司于2026年8月10日披露《关于归还用于临时补充流动资金的闲置募集资金的公告》。截至2026年8月10日，公司已将实际用于临时补充流动资金的闲置募集资金54,992.29万元全部归还至募集资金专项账户，使用期限未超过12个月，并已通知保荐机构及保荐代表人。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000034361.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657262102","title":"百洋医药新提交“迪巧小粉条”商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2657262102","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657262102?lang=zh_cn&edition=full","pubTime":"2026-08-08 07:19","pubTimestamp":1786144757,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示，近日美国安士制药有限公司新提交“迪巧小粉条”商标注册申请。商标申请详情如下：今年以来美国安士制药有限公司新申请注册商标4件，截止目前公司共持有注册商标437件，另有171件商标尚在注册申请中。结合公司2025年年报财务数据，2025年公司在研发方面投入了4216.52万元，同比增16.67%。通过天眼查大数据分析，青岛百洋医药股份有限公司共对外投资了36家企业，参与招投标项目332次；财产线索方面有商标信息570条，专利信息74条，著作权信息137条；此外企业还拥有行政许可64个。数据来源：天眼查APP以上内容为证券之星据公开信息整理，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080800005871.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652740679","title":"7月17日百洋医药跌6.32%，益民创新优势混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652740679","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652740679?lang=zh_cn&edition=full","pubTime":"2026-07-17 16:58","pubTimestamp":1784278711,"startTime":"0","endTime":"0","summary":"证券之星消息，7月17日百洋医药跌6.32%，收盘报22.23元，换手率3.07%，成交量16.13万手，成交额3.68亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为益民基金的益民创新优势混合A。马泉林在任的基金产品包括:益民优势安享混合A，管理时间为2022年9月5日至今，期间收益率为40.86%；益民创新优势混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700030772.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652406555","title":"百洋医药：提供ZAP-X放疗设备及配套技术支持","url":"https://stock-news.laohu8.com/highlight/detail?id=2652406555","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652406555?lang=zh_cn&edition=full","pubTime":"2026-07-17 16:42","pubTimestamp":1784277726,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药07月17日在投资者关系平台上答复投资者关心的问题。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700030388.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650920034","title":"百洋医药（301015）披露为子公司提供担保的进展公告，7月9日股价上涨2.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650920034","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650920034?lang=zh_cn&edition=full","pubTime":"2026-07-09 22:30","pubTimestamp":1783607434,"startTime":"0","endTime":"0","summary":"截至2026年7月9日收盘，百洋医药报收于22.08元，较前一交易日上涨2.94%，最新总市值为116.06亿元。该股当日开盘21.51元，最高22.6元，最低21.3元，成交额达2.58亿元，换手率为2.22%。公司于2026年7月9日发布《关于为子公司提供担保的进展公告》。上述担保事项均在公司2025年年度股东会审议通过的担保额度范围内，无需另行履行审议程序。本次担保后，公司及控股子公司对外担保总余额为37,852.16万元，占公司最近一期经审计净资产的15.37%，无逾期担保。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900042593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649952508","title":"百洋医药：不存在使用募集资金解除控股股东股票质押的情形","url":"https://stock-news.laohu8.com/highlight/detail?id=2649952508","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649952508?lang=zh_cn&edition=full","pubTime":"2026-07-08 11:36","pubTimestamp":1783481768,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药(301015)07月07日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，你好，港股上市什么时候开始提交相关资料？港股上市后的融资的资金会用于解除质押股票吗？百洋医药回复：投资者您好，港股发行进展情况请关注公司后续公告，募集资金可能用于（包括但不限于）产品的研发、生产与商业化平台投入、新产品引进、销售渠道建设与推广投入、运营资金及其他一般公司用途等方面，不存在使用募集资金解除控股股东股票质押的情形，感谢您的关注与支持。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800018646.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648051643","title":"7月1日百洋医药涨5.46%，益民创新优势混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2648051643","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648051643?lang=zh_cn&edition=full","pubTime":"2026-07-01 16:55","pubTimestamp":1782896103,"startTime":"0","endTime":"0","summary":"证券之星消息，7月1日百洋医药涨5.46%，收盘报20.1元，换手率1.3%，成交量6.84万手，成交额1.34亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为益民基金的益民创新优势混合A。马泉林在任的基金产品包括:益民优势安享混合A，管理时间为2022年9月5日至今，期间收益率为55.71%；益民创新优势混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100031762.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648518100","title":"百洋医药：控股股东所持股份质押比例处于合理可控范围","url":"https://stock-news.laohu8.com/highlight/detail?id=2648518100","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648518100?lang=zh_cn&edition=full","pubTime":"2026-07-01 15:21","pubTimestamp":1782890478,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药(301015)07月01日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，公司股权质押接近50%，严重偏高，是否是资金存在严重问题，近期是否有计划解押降低股权质押？百洋医药回复：投资者您好，控股股东质押资金用途为满足其生产经营、补充流动资金等需求，属于控股股东自身融资安排。截至目前，控股股东所持股份质押比例处于合理可控范围，不存在平仓风险，控股股东资信状况良好具备相应偿付能力，感谢您的关注与支持。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100023715.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647013963","title":"股市必读：百洋医药（301015）6月29日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2647013963","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647013963?lang=zh_cn&edition=full","pubTime":"2026-06-30 02:39","pubTimestamp":1782758349,"startTime":"0","endTime":"0","summary":"截至2026年6月29日收盘，百洋医药报收于19.8元，上涨3.45%，换手率1.55%，成交量8.16万手，成交额1.6亿元。董秘最新回复投资者： 股价又要往新低去了，大股东这边的质押是否安全？董秘： 投资者您好，截至目前，公司控股股东所持股份质押比例低于50%，质押比例处于合理可控范围，不存在平仓风险。当日关注点交易信息汇总：6月29日主力资金净流出184.61万元，游资资金净流出524.64万元，散户资金净流入709.25万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000001617.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647378677","title":"百洋医药（301015）披露拟发行H股并在港交所主板上市议案，6月29日股价上涨3.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2647378677","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647378677?lang=zh_cn&edition=full","pubTime":"2026-06-29 18:00","pubTimestamp":1782727255,"startTime":"0","endTime":"0","summary":"截至2026年6月29日收盘，百洋医药报收于19.8元，较前一交易日上涨3.45%，最新总市值为104.07亿元。该股当日开盘19.1元，最高20.39元，最低18.5元，成交额达1.6亿元，换手率为1.55%。会议表决结果均获有效通过。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900028689.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015","HEXmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647324324","title":"百洋医药：公司目前经营一切正常","url":"https://stock-news.laohu8.com/highlight/detail?id=2647324324","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647324324?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:18","pubTimestamp":1782721094,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药(301015)06月29日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，创业板指数在不断创新高，而百洋医药又是属于创业板的，还老是跌跌不休，我想问这是什么原因？是创新药转型受阻了吗？公司无计划增持自救保护投资者利益吗？百洋医药回复：投资者您好，股价波动受宏观经济、行业周期、市场情绪等多重复杂因素影响，公司目前经营一切正常，管理层始终重视投资者利益，若未来有相关计划，公司将严格按照相关规定及时履行信息披露义务，感谢您的关注与支持。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900023357.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646547213","title":"百洋医药：公司及控股子公司无逾期担保情况","url":"https://stock-news.laohu8.com/highlight/detail?id=2646547213","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646547213?lang=zh_cn&edition=full","pubTime":"2026-06-26 19:15","pubTimestamp":1782472500,"startTime":"0","endTime":"0","summary":"证券日报网讯 6月26日，百洋医药发布公告称，公司及公司控股子公司不存在对合并报表外单位提供担保的情况。公司及控股子公司无逾期担保情况，无涉及诉讼的担保事项，不存在因担保被判决败诉而应承担损失的情形。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-06-26/doc-inietwvk0442697.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-06-26/doc-inietwvk0442697.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0250","301015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645685301","title":"股市必读：百洋医药（301015）6月23日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2645685301","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645685301?lang=zh_cn&edition=full","pubTime":"2026-06-24 01:59","pubTimestamp":1782237548,"startTime":"0","endTime":"0","summary":"截至2026年6月23日收盘，百洋医药报收于19.7元，下跌0.56%，换手率1.22%，成交量6.39万手，成交额1.28亿元。董秘最新回复投资者： 请问，锝[99mTc]佩昔瑞特加肽注射液自上市以来，是否医院已经开出第一单了，患者使用效果如何？董秘： 投资者您好，锝[99mTc]佩昔瑞特加肽注射液是我国第一个自主研发的核医学1类创新药，全球首个用于SPECT显像诊断的广谱肿瘤显像药物。当日关注点交易信息汇总：6月23日主力资金净流出1808.43万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400001365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645288556","title":"百洋医药：锝[99mTc]佩昔瑞特加肽注射液是我国第一个自主研发的核医学1类创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2645288556","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645288556?lang=zh_cn&edition=full","pubTime":"2026-06-23 15:00","pubTimestamp":1782198045,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药(301015)06月23日在投资者关系平台上答复投资者关心的问题。投资者提问：请问，锝[99mTc]佩昔瑞特加肽注射液自上市以来，是否医院已经开出第一单了，患者使用效果如何？百洋医药回复：投资者您好，锝[99mTc]佩昔瑞特加肽注射液是我国第一个自主研发的核医学1类创新药，全球首个用于SPECT显像诊断的广谱肿瘤显像药物。目前公司正按照经营计划有序进行商业化推广工作，感谢您的关注与支持。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300020087.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","301015","06978","159992","BK1574","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645260040","title":"6月22日百洋医药跌6.91%，益民创新优势混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645260040","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645260040?lang=zh_cn&edition=full","pubTime":"2026-06-22 16:51","pubTimestamp":1782118298,"startTime":"0","endTime":"0","summary":"根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为益民基金的益民创新优势混合A。马泉林在任的基金产品包括:益民优势安享混合A，管理时间为2022年9月5日至今，期间收益率为48.98%；益民创新优势混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200024015.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645150095","title":"每周股票复盘：百洋医药（301015）百洋转债或触向下修正条件","url":"https://stock-news.laohu8.com/highlight/detail?id=2645150095","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645150095?lang=zh_cn&edition=full","pubTime":"2026-06-21 01:58","pubTimestamp":1781978292,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，百洋医药报收于21.28元，较上周的20.37元上涨4.47%。本周，百洋医药6月18日盘中最高价报21.65元。本周关注点公司公告汇总：百洋转债连续十日收盘价低于转股价85%，或触发向下修正条件公司公告汇总关于预计触发百洋转债转股价格向下修正条件的提示性公告青岛百洋医药股份有限公司发布关于预计触发“百洋转债”转股价格向下修正条件的提示性公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062100000446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644085778","title":"百洋医药：为深入推进公司全球化发展战略及海外业务布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2644085778","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644085778?lang=zh_cn&edition=full","pubTime":"2026-06-18 20:51","pubTimestamp":1781787093,"startTime":"0","endTime":"0","summary":"百洋医药回复：投资者您好，为深入推进公司全球化发展战略及海外业务布局，充分借助国际资本市场的资源与机制优势，提升品牌影响力与核心竞争力，公司积极推进H股发行上市；公司始终高度重视全体股东的权益，将继续深耕主业，优化经营质量，努力提升公司内在价值，为股东创造长期、可持续的回报，感谢您的关注与支持。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800040511.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643318765","title":"百洋医药（301015）披露关于预计触发百洋转债转股价格向下修正条件的提示性公告，6月16日股价下跌0.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2643318765","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2643318765?lang=zh_cn&edition=full","pubTime":"2026-06-16 22:46","pubTimestamp":1781621176,"startTime":"0","endTime":"0","summary":"截至2026年6月16日收盘，百洋医药报收于20.39元，较前一交易日下跌0.39%，最新总市值为107.17亿元。该股当日开盘20.37元，最高20.63元，最低20.05元，成交额达5483.8万元，换手率为0.52%。青岛百洋医药股份有限公司于2026年6月16日发布《关于预计触发百洋转债转股价格向下修正条件的提示性公告》。根据相关规定，若在未来持续满足条件，公司董事会需审议是否修正转股价格，并及时履行信息披露义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061600044447.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642440604","title":"百洋医药最新公告：筹划发行H股并在香港联交所主板上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2642440604","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2642440604?lang=zh_cn&edition=full","pubTime":"2026-06-10 18:31","pubTimestamp":1781087493,"startTime":"0","endTime":"0","summary":"百洋医药(301015.SZ)公告称，公司拟公开发行H股股票并在香港联交所主板上市，以推进全球化战略、优化资本结构，相关决议有效期为股东会审议通过之日起24个月。本次发行尚需获得证监会、香港联交所等监管机构批准，存在不确定性。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061000033048.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640415556","title":"百洋医药：纽特舒玛国内蝉联进口纯乳清蛋白粉销售额第一","url":"https://stock-news.laohu8.com/highlight/detail?id=2640415556","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640415556?lang=zh_cn&edition=full","pubTime":"2026-06-04 17:00","pubTimestamp":1780563646,"startTime":"0","endTime":"0","summary":"证券之星消息，百洋医药06月04日在投资者关系平台上答复投资者关心的问题。公司自有品牌纽特舒玛的市场空间完全打开了，有可能再造一个迪巧。请问纽特舒玛在美国销售是否爆发增长？百洋医药回复：投资者您好，纽特舒玛中美同步运营、国内蝉联进口纯乳清蛋白粉销售额第一，销售保持快速增长，2025年纽特舒玛系列产品实现营业收入1.69亿元，同比增长39.65%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060400029143.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301015","BK0250"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787147690120,"stockEarnings":[{"period":"1week","weight":0.0908},{"period":"1month","weight":0.2047},{"period":"3month","weight":0.2231},{"period":"6month","weight":0.1744},{"period":"1year","weight":0.0513},{"period":"ytd","weight":0.1645}],"compareEarnings":[{"period":"1week","weight":0.0143},{"period":"1month","weight":0.0601},{"period":"3month","weight":-0.0413},{"period":"6month","weight":-0.0225},{"period":"1year","weight":0.0704},{"period":"ytd","weight":0.0054}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"青岛百洋医药股份有限公司","boardCode":"AI0051","boardName":"批发业","stockholders":"14963人(较上一季度增加8.92%)","perCapita":"35123股","listingDate":"2021-06-30","address":"山东省青岛市市北区桐柏路88号1号楼","registeredCapital":"52562万元","survey":" 青岛百洋医药股份有限公司核心业务聚焦医学创新成果的产品开发、生产制造和商业化运营,公司深度布局创新药与创新医疗器械，聚焦骨健康、抗器官纤维化、肿瘤脑转移、心血管等前沿领域，通过投资、研发转化与产业化平台运营，构建从源头创新到临床落地的全链条产业生态。公司的主要产品是药品、医疗器械、品牌服务。","listedPrice":7.64},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百洋医药(301015)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百洋医药(301015)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百洋医药,301015,百洋医药股票,百洋医药股票老虎,百洋医药股票老虎国际,百洋医药行情,百洋医药股票行情,百洋医药股价,百洋医药股市,百洋医药股票价格,百洋医药股票交易,百洋医药股票购买,百洋医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百洋医药(301015)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百洋医药(301015)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}